ERYTECH provides financial update for Q1 2013 Post author:admERY Post published:June 3, 2013 Post category:Newsroom ERYTECH announced today its cash position and its revenues for first quarter 2013. You Might Also Like ERYTECH Pharma receives FDA IND clearance to initiate a clinical study in Acute Lymphoblastic Leukemia in the U.S. April 3, 2013 ERYTECH Announces Commencement of Trading of ADSs on Nasdaq and Full Exercise of Underwriters’ Option, Bringing Gross Proceeds of Global Offering to $144 Million November 15, 2017 ERYTECH Achieves Milestones in TRYbeCA1 Phase 3 Trial of Eryaspase in Second-line Pancreatic Cancer November 4, 2019
ERYTECH Pharma receives FDA IND clearance to initiate a clinical study in Acute Lymphoblastic Leukemia in the U.S. April 3, 2013
ERYTECH Announces Commencement of Trading of ADSs on Nasdaq and Full Exercise of Underwriters’ Option, Bringing Gross Proceeds of Global Offering to $144 Million November 15, 2017
ERYTECH Achieves Milestones in TRYbeCA1 Phase 3 Trial of Eryaspase in Second-line Pancreatic Cancer November 4, 2019
